WASHINGTON — The Association for Accessible Medicines has applauded the proclamation signed today by President Trump announcing the final results of a Section 232 investigation into possible tariffs and trade issues concerning pharmaceuticals. The investigation started in April of last year.
“The generics and biosimilars industry applaud the Administration for recognizing the unique aspects of our industry’s supply chain and exempting generic and biosimilar medicines from tariffs under this 232 investigation,” said John Murphy III, President and CEO of the Association for Accessible Medicines. “We are especially grateful to the Administration for working with AAM and the Biosimilars Council along with our member companies over the last year to discuss the unique aspects of the generics ecosystem and explore ways to strengthen both the resiliency of the overall supply chain as well as enhance the ability of the industry to grow here in the U.S.
“There was a clear appreciation and understanding of the savings and access provided to American patients, as well as the potential harms and unintended consequences associated with further burdening the economics of our industry in the U.S.
“This decision will help enhance the generic medicines supply chain, which is critical to patient health and U.S. healthcare and national security interests. We look forward to continuing to work with the Administration, Congress, and key stakeholders on reforms that prioritize patients, enhance the industry’s U.S. footprint, strengthen our national security, and ultimately increase access for American patients to a reliable lower-cost medicines ecosystem.”
